Loading…
Ending the Diagnostic Odyssey Act of 2019
Legislative Progress
Introduced
December 19, 2019
Latest Action
December 19, 2019
Primary Sponsor
Susan M. CollinsRepublican(ME)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Ending the Diagnostic Odyssey Act of 2019 This bill allows state Medicaid programs to cover whole genome sequencing services for certain individuals. Specifically, states may cover such services for individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26 who (1) have been referred or admitted to an intensive care unit or seen by a medical specialist for a suspected genetic or undiagnosed disease, or (2) are suspected by a medical specialist to have a neonatal- or pediatric-onset genetic disease. The Centers for Medicare & Medicaid Services may award grants to assist states in developing plans to cover such services.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2021 · first_quarter · Medicare/Medicaid
(NO BILL #) - ENDING THE DIAGNOSTIC ODYSSEY ACT (fka: HR 4144 & S 3116 - 116TH CONGRESS); ALL PROVISIONS OF THE ACT
Client expense: $290,000 · Firm income: Not reported
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S7211)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $270,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2020 · fourth_quarter · Health Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019; Public Law 116-136 - CARES Act; Public Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, The Heroes Act; H.R. 925, The Heroes Act; CDC surveillance funding; CURES 2.0 discussion draft; H.R. 133/P.L. 116-260, Consolidated Appropriations Act, 2021
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Allergy policies (H.R 2009, S.2246) Diagnostic test reimbursement and policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID-19 preparedness products and services PASTEUR Act (S.4760)
Client expense: $230,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2020 · third_quarter · Medicare/Medicaid
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2020 · third_quarter · Health Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019; Public Law 116-136 - CARES Act; Public Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, The Heroes Act; H.R. 925, The Heroes Act; CDC surveillance funding; CURES 2.0 discussion draft
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Allergy policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID-19 diagnostics, testing, supplies, vaccines, manufacturing & procurement PASTEUR Act (S.4760)
Client expense: $370,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2020 · second_quarter · Health Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement. H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019; Public Law 116-136 - CARES Act; Public Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act; H.R.6800, The Heroes Act; CDC surveillance funding
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
Allergy policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID-19 diagnostics, testing, supplies, vaccines, manufacturing & procurement
Client expense: $260,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2020 · first_quarter · Health Issues
H.R. 748 (P.L. No: 116-136): CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6074 (P.L. No: 116-123) - CORONAVIRUS PREPAREDNESS AND RESPONSE SUPPLEMENTAL APPROPRIATIONS ACT, 2020; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE H.R. 6201 (P.L. No: 116-127): FAMILIES FIRST CORONAVIRUS RESPONSE ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $180,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
H.R. 748 (P.L. No: 116-136): CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6074 (P.L. No: 116-123) - CORONAVIRUS PREPAREDNESS AND RESPONSE SUPPLEMENTAL APPROPRIATIONS ACT, 2020; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE H.R. 6201 (P.L. No: 116-127): FAMILIES FIRST CORONAVIRUS RESPONSE ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $180,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019; H.R. 748 (Public Law 116-136), CARES Act - issues related to Next Generation Sequencing (NGS) and surveillance funding
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
Asthma policies (H.R 2009, S.2246) Diagnostic test reimbursement & policies DISARM Act (H.R. 4100, S.1712) Precision Medicine (H.R. 4393, S. 3116) COVID preparedness products and services (H.R. 748)
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
2019 · fourth_quarter · Health Issues
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · fourth_quarter · Health Issues
H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| MN |